Big data used to identify a potential drug for Parkinson’s disease
Big data analysis suggests that terazosin, an approved prostate cancer drug, shows activity in blocking cell death and hence could be used to treat Parkinson’s disease by targeting a hallmark of this disease – reduced cellular energy production.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>